Fulcrum Therapeutics
FULC
68 hedge funds and large institutions have $317M invested in Fulcrum Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 8 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
24% more capital invested
Capital invested by funds: $256M → $317M (+$60.8M)
3% more funds holding
Funds holding: 66 → 68 (+2)
1.64% more ownership
Funds ownership: 80.74% → 82.38% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$18.9M |
| 2 |
RI
RTW Investments
New York
|
+$14M |
| 3 |
CAC
Cowen and Company
New York
|
+$10.9M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$10.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.43M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.3M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$2.69M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.03M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$742K |
FULC Hedge Fund Activity: Q1 2021 in Review
68 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q1 2021, worth a combined $317M — up 24% from $256M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new FULC positions and 8 closed out — a net gain of 2 holders — while 24 added to existing stakes and 16 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $18.9M. The largest seller was Point72 Asset Management, cutting an estimated $9.43M.
- 68 institutional investors held Fulcrum Therapeutics (FULC) as of Q1 2021, up from 66 in Q4 2020.
- Funds reported $317M of Fulcrum Therapeutics stock for Q1 2021, up 24% quarter-over-quarter.
- 10 funds opened new Fulcrum Therapeutics positions in Q1 2021 and 8 closed out, a net change of +2 holders.
- The largest Fulcrum Therapeutics buyer in Q1 2021 was Suvretta Capital Management, an estimated $18.9M added.
- The largest Fulcrum Therapeutics seller in Q1 2021 was Point72 Asset Management, an estimated $9.43M sold.
Based on aggregated 13F filings for Q1 2021.